https://www.selleckchem.com/products/ly333531.html
93min (95% CI 8.25-11.61), and the mean difference of ESS score was-4.44 (95% CI-5.50 to-3.38), both in favor of solriamfetol over placebo. The overall risk ratio of adverse events with solriamfetol was 1.47 (95% CI 1.28-1.69). The most common adverse events reported were headache, nausea, decreased appetite, anxiety, nasopharyngitis, and insomnia. Solriamfetol is efficacious and has a favorable safety profile in the treatment of EDS in patients with narcolepsy and OSA. Solriamfetol is well tolerated and may be recommended for the trea
Like
Comment
Share
